Despite media reports, the idea of an "FDA for AI" that pre-approves models is not supported by key policy advisors. Insiders stress the goal is industry coordination to harden government systems against AI threats, not to create a Washington-based approval bottleneck that would kill innovation.

The traditional government model of setting a regulation and waiting years to assess it is obsolete for AI. A new approach is needed: a dynamic board of government, industry, and academic leaders collaborating to make and update rules in real-time.

Formal regulations are struggling to keep up with the breakneck speed of AI innovation. Consequently, the actual standards for AI governance will emerge organically from industry best practices, born from incident responses and cutting-edge research. These practical solutions will be adopted long before they are codified into law.

By voluntarily restricting access to its new Mythos AI model, Anthropic has provided a clear, real-world model for regulators to copy. This corporate self-regulation makes it far easier for government agencies to enforce similar 'behind closed doors' access policies on other AI labs in the future.

Facing growing moral panic, the AI industry's plan appears to be moving so fast that regulation becomes impossible. By building data centers and deploying models at breakneck speed, companies aim to make their technology ubiquitous before any effective policy can form.

Contrary to their current stance, major AI labs will pivot to support national-level regulation. The motivation is strategic: a single, predictable federal framework is preferable to navigating an increasingly complex and contradictory patchwork of state-by-state AI laws, which stifles innovation and increases compliance costs.

Silicon Valley's economic engine is "permissionless innovation"—the freedom to build without prior government approval. Proposed AI regulations requiring pre-approval for new models would dismantle this foundation, favoring large incumbents with lobbying power and stifling the startup ecosystem.

A new executive order proposes a 90-day government review period before new AI models can be released. This lengthy delay poses a significant threat to the AI industry's core competitive advantage: its breakneck speed of innovation and iteration. Such a slowdown could fundamentally alter the release cadence and competitive dynamics among the major labs.

An FDA-style regulatory model would force AI companies to make a quantitative safety case for their models before deployment. This shifts the burden of proof from regulators to creators, creating powerful financial incentives for labs to invest heavily in safety research, much like pharmaceutical companies invest in clinical trials.